

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM657645

| | | | |
|---|--|-----------------------|-------------------------|
| SUBMISSION TYPE: | NEW ASSIGNMENT | | |
| NATURE OF CONVEYANCE: | ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL | | |
| CONVEYING PARTY DATA | | | |
| Name | Formerly | Execution Date | Entity Type |
| Glaxo Group Limited | | 07/02/2021 | Company: UNITED KINGDOM |
| RECEIVING PARTY DATA | | | |
| Name: | Woodward Pharma Services LLC | | |
| Street Address: | 47220 Cartier Drive, Suite A | | |
| City: | Wixom | | |
| State/Country: | MICHIGAN | | |
| Postal Code: | 48393 | | |
| Entity Type: | Limited Liability Company: MICHIGAN | | |
| PROPERTY NUMBERS Total: 1 | | | |
| Property Type | Number | Word Mark | |
| Registration Number: | 4003717 | JALYN | |
| CORRESPONDENCE DATA | | | |
| Fax Number: | 6167522500 | | |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> | | | |
| Phone: | 6167522479 | | |
| Email: | trademarks@wnj.com | | |
| Correspondent Name: | R. Scott Keller Warner Norcross + Judd | | |
| Address Line 1: | 150 Ottawa Avenue NW, Suite 1500 | | |
| Address Line 4: | Grand Rapids, MICHIGAN 49503 | | |
| NAME OF SUBMITTER: | R. Scott Keller | | |
| SIGNATURE: | /rsk/ | | |
| DATE SIGNED: | 07/02/2021 | | |
| Total Attachments: 18 | | | |
| source=Project EcWoodward Pharma GSK TM assignment#page1.tif | | | |
| source=Project EcWoodward Pharma GSK TM assignment#page2.tif | | | |
| source=Project EcWoodward Pharma GSK TM assignment#page3.tif | | | |
| source=Project EcWoodward Pharma GSK TM assignment#page4.tif | | | |
| source=Project EcWoodward Pharma GSK TM assignment#page5.tif | | | |
| source=Project EcWoodward Pharma GSK TM assignment#page6.tif | | | |

OP \$40.00 4003717

source=Project EcWoodward Pharma GSK TM assignment#page7.tif
source=Project EcWoodward Pharma GSK TM assignment#page8.tif
source=Project EcWoodward Pharma GSK TM assignment#page9.tif
source=Project EcWoodward Pharma GSK TM assignment#page10.tif
source=Project EcWoodward Pharma GSK TM assignment#page11.tif
source=Project EcWoodward Pharma GSK TM assignment#page12.tif
source=Project EcWoodward Pharma GSK TM assignment#page13.tif
source=Project EcWoodward Pharma GSK TM assignment#page14.tif
source=Project EcWoodward Pharma GSK TM assignment#page15.tif
source=Project EcWoodward Pharma GSK TM assignment#page16.tif
source=Project EcWoodward Pharma GSK TM assignment#page17.tif
source=Project EcWoodward Pharma GSK TM assignment#page18.tif

TRADEMARK AND DOMAIN NAME ASSIGNMENT

This TRADEMARK AND DOMAIN NAME ASSIGNMENT (this “**Assignment**”), dated July 2, 2021, (the “**Effective Date**”), is between (i) **GLAXO GROUP LIMITED**, a company registered in England, with registered office located at 980 Great West Road, Brentford, Middlesex, TW8 9GS England (“**GGL**”), **GLAXOSMITHKLINE LLC**, a Delaware limited liability company, with registered office located at 251 Little Falls Drive, Corporation Service Company, Wilmington, DE 19808, United States (“**GSK**”), **SMITHKLINE BEECHAM LIMITED**, a company registered in England, with registered office located at 980 Great West Road, Brentford, Middlesex, TW8 9GS England (“**SKB**”), and **SMITHKLINE BEECHAM (CORK) LIMITED**, a company organized under the laws of the Republic of Ireland with registered offices located at 12 Riverwalk, Citywest Business Campus, Dublin 24 Ireland (“**SKB (Cork)**”), and together with GGL, GSK and SKB, collectively referred to herein as the “**Assignor**”) and (ii) **WOODWARD PHARMA SERVICES LLC**, a Michigan limited liability company, with a place of business at 47220 Cartier Dr., Suite A, Wixom, Michigan 48393 (the “**Assignee**” and, collectively with the Assignor, the “**Parties**”).

A. Assignee, GSK, SKB (Cork) and GlaxoSmithKline Trading Services Limited (registered number 406446), a company organized and existing under the laws of Ireland, having its registered office at 12 Riverwalk, Citywest Business Campus, Citywest, Dublin 24, Ireland, and having a UK principal place of business at 980 Great West Road, Brentford, Middlesex TW8 9GS, UK are party to an Asset Purchase Agreement, dated June 30, 2021 (as may be amended, restated or otherwise modified from time to time, the “**Purchase Agreement**”).

B. Under the Purchase Agreement, and subject to the terms thereof, the Assignor sold to the Assignee all of the Assignor’s rights, title, and interest in and to each Trademark and Internet domain name that is a Purchased Asset (each such Trademark, an “**Assigned Trademark**” and each such Internet domain name, an “**Assigned Domain Name**”, collectively, the “**Assigned Assets**”), including those Assigned Assets set forth in **Schedule A** and including all rights under common law relating to each Assigned Trademark, the corresponding registrations and applications for each Assigned Trademark, and the goodwill appurtenant to each of the foregoing.

The Parties hereby agree as follows:

- 1. Assignment.** The Assignor hereby assigns, transfers, delivers, and conveys to the Assignee, and the Assignee hereby purchases and acquires from the Assignor, all of the Assignor’s right, title, and interest in and to (a) each Assigned Trademark, including all rights under common law relating to each Assigned Trademark, the corresponding registrations in the U.S. Patent and Trademark Office for each Assigned Trademark (including any renewals and extensions of such registrations, now or hereafter in effect), and the goodwill appurtenant to each of the foregoing described in this clause (a); (b) each Assigned Domain Name (including any renewals of such registrations, now or hereafter in effect) and the goodwill appurtenant to each of the foregoing described in this clause (b); and (c) all rights to bring, make, oppose, defend, appeal proceedings, claims or actions, whether at law or in equity, for infringement, dilution, or misuse of each Assigned Asset against any Person, and all rights against any Person to recover damages, to recover profits,

and to secure injunctive relief for all past, present, or future infringement, dilution, or misuse of each Assigned Asset, in each case, other than the Retained Rights.

2. **Forfeiture of Domain Names.** If, at any point, that certain Trademark License Agreement, dated as of the date hereof, by and among GSK, SKB, SKB (Cork) and Assignee is terminated for any reason, then any and all right, title, and interest in and to each of those Assigned Domain Names identified in **Schedule B** (the “**Subject Domain Names**”) shall automatically be assigned back to the applicable Assignor thereof or to an Affiliate or other successor designated by Assignor, and the Parties shall cooperate to execute such documentation as may be reasonably requested by the Assignor to evidence such assignment as promptly as practicable following the effective date of such termination.
3. **Purchase Agreement Controls.** The terms hereof are subject in all respects to the terms of the Purchase Agreement, which is hereby incorporated herein by reference. Nothing herein in any way supersedes, enlarges, narrows, or modifies (and nothing herein will be deemed to supersede, enlarge, narrow, or modify) any provision of the Purchase Agreement, except as otherwise expressly set forth herein. If there is any conflict or inconsistency between the terms of the Purchase Agreement and the terms hereof, then the terms of the Purchase Agreement will control.
4. **Further Assurances.**
 - (a) Each Party hereto agrees to cooperate fully with the other Party to carry into effect the intents and purposes of this Assignment in accordance with the terms of the Purchase Agreement. Each Party agrees to undertake, at the Assignee’s expense (solely with respect to any third party fees), all such reasonable acts and/or execute or procure the execution of all documents as may be reasonably required by law or reasonably necessary to vest each Assigned Asset in the Assignee (or, solely in respect of the Subject Domain Names and to the extent provided in Section 2 to, the applicable Assignor) or otherwise perfect the legal and beneficial title of the Assignee (or, solely in respect of the Subject Domain Names and to the extent provided in Section 2 to, the applicable Assignor) in and to the Assigned Assets, including, with respect to the Assigned Domain Names, and without limitation: (a) unlocking the domain with the applicable registrar, (b) obtaining an authorization code for the transfer of the Assigned Domain Name from the applicable registrar, and (c) notifying Assignee of the completion of part (a) and (b) and providing such authorization code to Assignee (“**Initiation Notification**”). Assignee shall promptly complete the transfer upon its receipt of the Initiation Notification.
 - (b) Notwithstanding the foregoing paragraph or any provision of the Purchase Agreement, if a period of twelve (12) months passes from the Effective Date and the recordal of the assignment of any Assigned Asset has not been initiated by the Assignee, and the Assigned Trademarks and/or Assigned Domain Names remain in the name of the Assignor in the records of the relevant trademark registry or

domain name registrar, the Assignor shall have no obligation to renew, maintain, or pay any fees in connection with such Assigned Trademark or Assigned Domain Name; provided, that the Assignor shall have no obligation to renew, refile, maintain, pay any fees or take other action from and after the date hereof with respect to any Assigned Trademark or Assigned Domain Name not in use by the Assignor or its Affiliates as of the date hereof.

- (c) Assignor hereby covenants and agrees that neither Assignor nor any of its Affiliates shall make any commercial use of the Internet domain name “Avodart.com” (the “**Restricted Domain Name**”) in connection with the marketing and Distribution of Products within the Territory; provided, that for the avoidance of doubt, the Restricted Domain Name shall not constitute an Assigned Domain Name for any purpose hereunder and Assignor and its Affiliates shall retain all rights, title and interest in and to the Restricted Domain Name.
- (d) If at any time Assignor and its Affiliates shall have made a final determination to discontinue the marketing and Distribution of Avodart outside of the Territory (other than in connection with a transaction contemplated by Section 4(e) but subject to the terms thereof) and shall have made a final determination to cease use of the Restricted Domain Name, Assignor will notify Assignee of such decision in writing (such notice, the “**Avodart.com Notice**”), which Avodart.com Notice shall specify the purchase price for and other terms upon which Assignor and its Affiliates would be willing to sell, assign, transfer, deliver and convey to the Assignee or one of its Affiliates all of Assignor’s and its Affiliates’ right, title and interest in and to the Restricted Domain Name. Within a period of thirty (30) days following Assignee’s receipt of the Avodart.com Notice, Assignee or one of its Affiliates may deliver to Assignor written notice (an “**Acceptance Notice**”) that Assignee or such Affiliate of Assignee elects to enter into an agreement with Assignor or its applicable Affiliate(s) on the terms and conditions described in the Avodart.com Notice and such other terms as may be agreed between the parties in a definitive agreement with respect to the transactions contemplated by the Avodart.com Notice (a “**Definitive Agreement**”). If Assignee or such Affiliate so elects, then Assignor or its applicable Affiliate(s) will negotiate with Assignee in good faith to enter into an agreement with Assignee or its applicable Affiliate(s) on the terms and conditions set forth in the Avodart.com Notice. If Assignee does not deliver an Acceptance Notice within such time period or does not enter into a Definitive Agreement with Assignor or its applicable Affiliate(s) within sixty (60) days of delivering the Acceptance Notice, then Assignor and its Affiliates shall have no further restriction or obligation to Assignee or its Affiliates concerning the transactions contemplated by the Avodart.com Notice.
- (e) Nothing herein shall restrict Assignor from transferring, selling, licensing or assigning to any Third Party any right, title or interest in, to or under the Restricted Domain Name; provided, that the transferee, licensee or assignee, as applicable, of

such transfer, sale, license or assignment assumes in writing, at the time of the closing of such transfer, sale, license or assignment, the obligations of Assignor under Section 4(c) and Section 4(d).

5. Miscellaneous.

(a) Amendments; Waivers.

- (i) This Assignment can be amended if, and only if, such amendment is in writing and is signed by each Party.
- (ii) No waiver by any Party of such Party's rights, powers, or privileges hereunder, will be binding against the other Party. No such waiver by a Party will be enforceable against such Party unless such waiver was given in a written instrument signed by such Party. The waiver by any Party of any of such Party's rights, powers, or privileges hereunder arising because of any claimed breach, default, or misrepresentation under or with respect to a provision hereof, whether intentional or not, will not thereby extend (and will not be deemed to thereby extend) to any prior separate or subsequent breach, default, or misrepresentation, respectively, by such Party and will not affect in any way any rights, powers, or privileges arising by virtue of any such prior separate or subsequent occurrence. No failure or delay by any Party in exercising any of such Party's rights, powers, or privileges hereunder will operate as a waiver thereof, nor will any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power, or privilege hereunder or otherwise.
- (iii) Emails, including emails that bear an electronic "signature block" identifying the sender, do not constitute signed writings for purposes of this Section 5(a).

(b) Governing Law. This Assignment is governed by, and is to be interpreted and enforced in accordance with, the internal Laws of the State of Delaware without giving effect to any choice of law or conflict of laws rules or provisions (whether of the State of Delaware or any other jurisdiction) that would cause the application of the Laws of any jurisdiction other than the State of Delaware.

(c) Counterparts. Each Party is permitted to execute this Assignment in multiple counterparts, each of which will be deemed an original and all of which taken together will constitute one and the same instrument.

(d) Third-party Beneficiaries. No provision hereof is intended to confer, no provision hereof will confer, and no provision hereof will be deemed to confer benefits,

rights, or remedies upon any Person other than upon the Parties, their respective successors, and their respective permitted assigns.


- (e) **Entire Agreement.** This Assignment (i) is a final, complete, and exclusive statement of the agreement and understanding of the Parties with respect of the subject matter hereof, (ii) constitutes the entire agreement of the Parties with respect to the subject matter hereof, and (iii) supersedes, merges, and integrates herein any prior and contemporaneous negotiations, discussions, representations, understandings, and agreements between any of the Parties, whether oral or written, with respect to the subject matter hereof.
- (f) **Captions.** Titles, captions, and headings included herein are for convenience of reference only and are not to affect the meaning, construction, or interpretation hereof or of any provision hereof.
- (g) **Severability.** If any portion or provision hereof is to any extent determined to be illegal, invalid, or unenforceable by a court of competent jurisdiction, then the remainder hereof, and the application of such portion or provision in circumstances other than those as to which it is so determined to be illegal, invalid, or unenforceable, as applicable, will not be affected thereby. Without limiting the generality of the immediately foregoing sentence, if any portion or provision hereof is determined by any court of competent jurisdiction to be unenforceable by reason of excessive scope as to geographic, temporal, or functional coverage, then such provision will be deemed to extend only over the maximum geographic, temporal, and functional scope as to which such court determines it is permitted to be enforceable.
- (h) **Interpretation; Construction.**
 - (i) Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Purchase Agreement.
 - (ii) Unless otherwise expressly provided herein, any reference to a contract (including this Assignment) and all other contractual instruments is a reference to such contract or instrument (including all exhibits, schedules, annexes, indices, appendices, and other attachments thereto) as the same might be amended or otherwise modified in accordance with the terms thereof.
 - (iii) The Parties have participated jointly in the negotiation and drafting hereof, and any rule of construction or interpretation otherwise requiring this Assignment to be construed or interpreted against any Party by virtue of the authorship hereof is not to affect the construction and interpretation hereof.

- (i) **Adequate Consideration.** Each Party acknowledges that such Party has received adequate consideration to support such Party's entry into this Assignment and the promises made by such Party hereunder.

[Signature Page Follows]

IN WITNESS WHEREOF this Assignment has been executed the day and year appearing above.

GLAXO GROUP LIMITED

By: 

Name:

Title: John Sadler, Authorised signatory for and on behalf of The Wellcome Foundation Limited, Corporate Director of G


GLAXOSMITHKLINE LLC

By: _____

Name:

Title:

SMITHKLINE BEECHAM LIMITED

By: 

Name:

Title: John Sadler, Authorised signatory for and on behalf of Edinburgh Pharmaceutical Industries Limited

**SMITHKLINE BEECHAM (CORK)
LIMITED**

By: _____

Name:

Title:

WOODWARD PHARMA SERVICES LLC

By: _____

Name: David Risk

Title: Authorized Signatory

IN WITNESS WHEREOF this Assignment has been executed the day and year appearing above.

GLAXO GROUP LIMITED

By: _____
Name:
Title:

GLAXOSMITHKLINE LLC

By: *Hatixhe Hoxha*
Name: **Hatixhe Hoxha**
Title: **Assistant Secretary**

SMITHKLINE BEECHAM LIMITED

By: _____
Name:
Title:

**SMITHKLINE BEECHAM (CORK)
LIMITED**

By: _____
Name:
Title:


WOODWARD PHARMA SERVICES LLC

By: _____
Name: David Risk
Title: Authorized Signatory

[Signature Page to Trademark and Domain Name Assignment]

IN WITNESS WHEREOF this Assignment has been executed the day and year appearing above.


GLAXO GROUP LIMITED

By: 
Name: _____
Title: John Sadler, Authorised signatory for and on behalf of The Wellcome Foundation Limited, Corporate Director

GLAXOSMITHKLINE LLC

By: _____
Name: _____
Title: _____

SMITHKLINE BEECHAM LIMITED

By: 
Name: _____
Title: John Sadler, Authorised signatory for and on behalf of Edinburgh Pharmaceutical Industries Limited

SMITHKLINE BEECHAM (CORK) LIMITED

By: _____
Name: _____
Title: _____

WOODWARD PHARMA SERVICES LLC

By: _____
Name: David Risk
Title: Authorized Signatory

IN WITNESS WHEREOF this Assignment has been executed the day and year appearing above.

GLAXO GROUP LIMITED

By: _____
Name:
Title:

GLAXOSMITHKLINE LLC

By: _____
Name:
Title:

SMITHKLINE BEECHAM LIMITED

By: _____
Name:
Title:

**SMITHKLINE BEECHAM (CORK)
LIMITED**

By: Giuseppe Whelan Electronically signed
by: Giuseppe Whelan
Reason: I am signing
for the reasons as
stated in the document.
Date: Jun 29, 2021
13:12 GMT+1
Name: Giuseppe Whelan
Title: Director of SmithKline Beecham (Cork) Limited

WOODWARD PHARMA SERVICES LLC

By: _____
Name: David Risk
Title: Authorized Signatory

IN WITNESS WHEREOF this Assignment has been executed the day and year appearing above.

GLAXO GROUP LIMITED

By: _____
Name:
Title:

GLAXOSMITHKLINE LLC

By: _____
Name:
Title:


SMITHKLINE BEECHAM LIMITED

By: _____
Name:
Title:

**SMITHKLINE BEECHAM (CORK)
LIMITED**

By: _____
Name:
Title:

WOODWARD PHARMA SERVICES LLC

By:  _____
Name: David Risk
Title: Authorized Signatory

Schedule A
Assigned Trademarks

| Trademark | U.S. Registration No. | Registration Date | Assignor Party |
|---|------------------------------|--------------------------|-----------------------------------|
| 1-800-AVANDIA | 2437572 | 20 Mar 2001 | SmithKline Beecham (Cork) Limited |
| AVANDIA | 3074190 | 28 Mar 2006 | SmithKline Beecham (Cork) Limited |
| AVANDIA | 2241060 | 20 Apr 1999 | SmithKline Beecham (Cork) Limited |
| AVANDIA (STYLIZED)  | 2411346 | 5 Dec 2000 | SmithKline Beecham (Cork) Limited |
| AVANDIA (STYLIZED)  | 2534127 | 29 Jan 2002 | SmithKline Beecham (Cork) Limited |
| AVANDIA (STYLIZED)  | 2413102 | 12 Dec 2000 | SmithKline Beecham (Cork) Limited |
| AVANDIA (stylized) (in color) (teal/red)  | 2435863 | 13 Mar 2001 | SmithKline Beecham (Cork) Limited |
| AVANDIA.COM | 2437571 | 20 Mar 2001 | SmithKline Beecham (Cork) Limited |
| JALYN | 4003717 | 26 Jul 2011 | Glaxo Group Limited |

Assigned Domain Names

| Domain Name | Registration Date | Assignor Party |
|--------------------|--------------------------|-----------------------------------|
| avandia.com | 29 May 1998 | SmithKline Beecham (Cork) Limited |
| avandia.us | 19 Apr 2002 | SmithKline Beecham (Cork) Limited |
| avandiaaccess.com | 26 Feb 2009 | SmithKline Beecham (Cork) Limited |

| | | |
|------------------------------------|-------------|-----------------------------------|
| AvandiaAdvantage.com | 31 Aug 2006 | SmithKline Beecham (Cork) Limited |
| AvandiaAlerts.com | 27 Jun 2007 | SmithKline Beecham (Cork) Limited |
| Avandia-Alerts.com | 27 Jun 2007 | SmithKline Beecham (Cork) Limited |
| AvandiaandYou.com | 28 Jun 2007 | SmithKline Beecham (Cork) Limited |
| AvandiaBackground.com | 28 Jun 2007 | SmithKline Beecham (Cork) Limited |
| Avandia-ClassAction.com | 27 Jun 2007 | SmithKline Beecham (Cork) Limited |
| Avandia-ClassActionLawsuit.com | 27 Jun 2007 | SmithKline Beecham (Cork) Limited |
| AvandiaClassActionLawsuits.com | 27 Jun 2007 | SmithKline Beecham (Cork) Limited |
| Avandia-ClassActionLawsuits.com | 27 Jun 2007 | SmithKline Beecham (Cork) Limited |
| AvandiaClinicalTrials.com | 27 Jun 2007 | SmithKline Beecham (Cork) Limited |
| Avandia-ClinicalTrials.com | 27 Jun 2007 | SmithKline Beecham (Cork) Limited |
| AvandiaClinicalTrialsRegister.com | 27 Jun 2007 | SmithKline Beecham (Cork) Limited |
| Avandia-ClinicalTrialsRegister.com | 27 Jun 2007 | SmithKline Beecham (Cork) Limited |
| AvandiaConcern.com | 28 Jun 2007 | SmithKline Beecham (Cork) Limited |
| AvandiaConcerns.com | 28 Jun 2007 | SmithKline Beecham (Cork) Limited |
| AvandiaDetails.com | 28 Jun 2007 | SmithKline Beecham (Cork) Limited |
| avandiadiabetescare.com | 20 Oct 2006 | SmithKline Beecham (Cork) Limited |
| avandia-diabetescare.com | 20 Oct 2006 | SmithKline Beecham (Cork) Limited |
| avandiadiabetescareprogram.com | 20 Oct 2006 | SmithKline Beecham (Cork) Limited |
| avandia-diabetescareprogram.com | 20 Oct 2006 | SmithKline Beecham (Cork) Limited |
| avandiadirect.com | 30 Oct 2003 | Glaxo Group Limited |
| Avandia-Direct.com | 08 Dec 2003 | Glaxo Group Limited |
| avandiafact.com | 12 Jun 2007 | SmithKline Beecham (Cork) Limited |
| avandia-fact.com | 12 Jun 2007 | SmithKline Beecham (Cork) Limited |

| | | |
|---------------------------------------|-------------|-----------------------------------|
| avandia-facts.com | 12 Jun 2007 | SmithKline Beecham (Cork) Limited |
| AvandiaGetTheDetails.com | 28 Jun 2007 | SmithKline Beecham (Cork) Limited |
| avandiahcp.com | 13 Nov 2008 | SmithKline Beecham (Cork) Limited |
| AvandiaHealthcareProfessional.com | 10 Nov 2008 | SmithKline Beecham (Cork) Limited |
| Avandia-HealthcareProfessional.com | 10 Nov 2008 | SmithKline Beecham (Cork) Limited |
| AvandiaHealthcareProfessionals.com | 10 Nov 2008 | SmithKline Beecham (Cork) Limited |
| AvandiaHeartAttackRisk.com | 27 Jun 2007 | SmithKline Beecham (Cork) Limited |
| Avandia-HeartAttackRisk.com | 27 Jun 2007 | SmithKline Beecham (Cork) Limited |
| avandiaican.com | 29 Aug 2007 | SmithKline Beecham (Cork) Limited |
| avandia-ican.com | 18 Apr 2006 | SmithKline Beecham (Cork) Limited |
| AvandiaImportantSafetyInformation.com | 28 Jun 2007 | SmithKline Beecham (Cork) Limited |
| AvandiaISI.com | 28 Jun 2007 | SmithKline Beecham (Cork) Limited |
| avandia-joinican.com | 18 May 2006 | Glaxo Group Limited |
| AvandiaLitigationNews.com | 28 Jun 2007 | SmithKline Beecham (Cork) Limited |
| avandiamd.com | 29 Aug 2007 | SmithKline Beecham (Cork) Limited |
| avandiamedicinesaccess.com | 08 Nov 2010 | SmithKline Beecham (Cork) Limited |
| AvandiamedicinesREMS.com | 03 Feb 2011 | SmithKline Beecham (Cork) Limited |
| AvandiaNYou.com | 28 Jun 2007 | SmithKline Beecham (Cork) Limited |
| avandiapride.com | 23 Sep 2005 | Glaxo Group Limited |
| avandia-professional.com | 13 Nov 2008 | SmithKline Beecham (Cork) Limited |
| avandiaprogram.com | 02 Feb 2007 | SmithKline Beecham (Cork) Limited |
| avandia-program.com | 02 Feb 2007 | SmithKline Beecham (Cork) Limited |
| AvandiaQandA.com | 28 Jun 2007 | SmithKline Beecham (Cork) Limited |
| AvandiaQnA.com | 28 Jun 2007 | SmithKline Beecham (Cork) Limited |

| | | |
|--|-------------|-----------------------------------|
| AvandiaQuestion.com | 28 Jun 2007 | SmithKline Beecham (Cork) Limited |
| AvandiaQuestions.com | 28 Jun 2007 | SmithKline Beecham (Cork) Limited |
| AvandiaQuestionsAndAnswers.com | 28 Jun 2007 | SmithKline Beecham (Cork) Limited |
| AvandiaRecalls.com | 27 Jun 2007 | SmithKline Beecham (Cork) Limited |
| Avandia-Recalls.com | 27 Jun 2007 | SmithKline Beecham (Cork) Limited |
| Avandia-Risk.com | 28 Jun 2007 | SmithKline Beecham (Cork) Limited |
| avandia-rosiglitazone.com | 11 Apr 2012 | SmithKline Beecham (Cork) Limited |
| AvandiaRosiglitazoneMedicinesAccessprogram.com | 03 Feb 2011 | SmithKline Beecham (Cork) Limited |
| AvandiaSafety.com | 27 Jun 2007 | SmithKline Beecham (Cork) Limited |
| Avandia-Safety.com | 27 Jun 2007 | SmithKline Beecham (Cork) Limited |
| AvandiaSafetyAlert.com | 27 Jun 2007 | SmithKline Beecham (Cork) Limited |
| Avandia-SafetyAlert.com | 27 Jun 2007 | SmithKline Beecham (Cork) Limited |
| AvandiaSafetyAlerts.com | 27 Jun 2007 | SmithKline Beecham (Cork) Limited |
| Avandia-SafetyAlerts.com | 27 Jun 2007 | SmithKline Beecham (Cork) Limited |
| AvandiaSafetyConcern.com | 27 Jun 2007 | SmithKline Beecham (Cork) Limited |
| Avandia-SafetyConcern.com | 27 Jun 2007 | SmithKline Beecham (Cork) Limited |
| AvandiaSafetyConcerns.com | 27 Jun 2007 | SmithKline Beecham (Cork) Limited |
| Avandia-SafetyConcerns.com | 27 Jun 2007 | SmithKline Beecham (Cork) Limited |
| AvandiaSafetyInformation.com | 27 Jun 2007 | SmithKline Beecham (Cork) Limited |
| Avandia-SafetyInformation.com | 27 Jun 2007 | SmithKline Beecham (Cork) Limited |
| AvandiaSafetyProfile.com | 27 Jun 2007 | SmithKline Beecham (Cork) Limited |
| Avandia-SafetyProfile.com | 27 Jun 2007 | SmithKline Beecham (Cork) Limited |
| avandiasavings.com | 29 Aug 2007 | SmithKline Beecham (Cork) Limited |

| | | |
|--------------------------------------|-------------|-----------------------------------|
| AvandiaSideEffect.com | 27 Jun 2007 | SmithKline Beecham (Cork) Limited |
| Avandia-SideEffect.com | 27 Jun 2007 | SmithKline Beecham (Cork) Limited |
| avandiaspeakersedge.com | 01 Sep 2009 | SmithKline Beecham (Cork) Limited |
| avandiastraighttalk.com | 19 Jul 2007 | SmithKline Beecham (Cork) Limited |
| avandiasweepstakes.com | 24 Oct 2003 | Glaxo Group Limited |
| AvandiaWarnings.com | 27 Jun 2007 | SmithKline Beecham (Cork) Limited |
| Avandia-Warnings.com | 27 Jun 2007 | SmithKline Beecham (Cork) Limited |
| AvandiaWithdrawal.com | 27 Jun 2007 | SmithKline Beecham (Cork) Limited |
| Avandia-Withdrawal.com | 27 Jun 2007 | SmithKline Beecham (Cork) Limited |
| buyavandia.com | 31 Aug 2006 | SmithKline Beecham (Cork) Limited |
| Factsaboutavandia.com | 05 May 2010 | SmithKline Beecham Limited |
| joinavandia.com | 29 Aug 2007 | SmithKline Beecham (Cork) Limited |
| join-avandia.com | 07 Jun 2006 | SmithKline Beecham (Cork) Limited |
| MyAvandia.com | 28 Jun 2007 | SmithKline Beecham (Cork) Limited |
| SafetyofAvandia.com | 27 Jun 2007 | SmithKline Beecham (Cork) Limited |
| Thefactsaboutavandia.com | 05 May 2010 | SmithKline Beecham Limited |
| WhyAvandia.com | 28 Jun 2007 | SmithKline Beecham (Cork) Limited |
| WhyDidYourDoctorPrescribeAvandia.com | 28 Jun 2007 | SmithKline Beecham (Cork) Limited |
| WithAvandia.com | 28 Jun 2007 | SmithKline Beecham (Cork) Limited |
| YourAvandia.com | 28 Jun 2007 | SmithKline Beecham (Cork) Limited |
| 4jalyn.com | 15 Jun 2010 | Glaxo Group Limited |
| Aboutjalyn.com | 15 Jun 2010 | Glaxo Group Limited |
| jalyn.com | 03 Jan 1995 | Glaxo Group Limited |
| jalyn.org | 15 Jun 2010 | Glaxo Group Limited |
| Jalyndrug.com | 15 Jun 2010 | Glaxo Group Limited |
| Jalynfacts.com | 15 Jun 2010 | Glaxo Group Limited |

| | | |
|----------------|-------------|----------------------------|
| Jalynforme.com | 15 Jun 2010 | Glaxo Group Limited |
| Jalyninfo.com | 15 Jun 2010 | Glaxo Group Limited |
| Jalyntoday.com | 15 Jun 2010 | Glaxo Group Limited |
| Yourjalyn.com | 15 Jun 2010 | Glaxo Group Limited |
| Coreg.com | 13 Sep 2000 | SmithKline Beecham Limited |
| CoregCR.com | 26 Oct 2005 | SmithKline Beecham Limited |
| Goavodart.com | 31 Jul 2007 | SmithKline Beecham Limited |

Schedule B
Subject Domain Names

| Domain Name | Registration Date | Assignor Party |
|--------------------|--------------------------|----------------------------|
| Coreg.com | 13 Sep 2000 | SmithKline Beecham Limited |
| CoregCR.com | 26 Oct 2005 | SmithKline Beecham Limited |
| Goavodart.com | 31 Jul 2007 | SmithKline Beecham Limited |